Genome & Company (KOSDAQ:314130)

South Korea · Delayed Price · Currency is KRW

6,400.00

-350.00 (-5.19%)

At close: Feb 26, 2026

Revenue by Segment

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019
Pharmaceuticals	27.74B	14.30B	14.08B	451.25M	150.58M
Pharmaceuticals Growth	94.07%	1.50%	3021.27%	199.67%	228.54%
Total	27.74B	14.30B	14.08B	451.25M	150.58M
Total Growth	94.07%	1.50%	3021.27%	199.67%	228.54%

Revenue by Geography

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019
South Korea	6.30B	2.39B	14.08B	451.25M	150.58M
South Korea Growth	164.06%	-83.06%	3021.27%	199.67%	228.54%
Asia	4.43B	7.19B	-	-	-
Asia Growth	-38.40%	-	-	-	-
Europe	7.37B	269.13M	-	-	-
Europe Growth	2639.14%	-	-	-	-
South America	29.46M	15.04M	-	-	-
South America Growth	95.83%	-	-	-	-
North America	9.60B	4.39B	-	-	-
North America Growth	118.98%	-	-	-	-
Oceania	10.97M	52.16M	-	-	-
Oceania Growth	-78.98%	-	-	-	-
Total	27.74B	14.30B	14.08B	451.25M	150.58M
Total Growth	94.07%	1.50%	3021.27%	199.67%	228.54%

Source: S&P Global Market Intelligence.